Table 1 Potential drugs for high-risk and low-risk groups.
Group | Drug name | Clinical_phase | Mechanism of action | sRGES |
|---|---|---|---|---|
High_risk | Etamsylate | Launched | Haemostatic agent | − 0.37159 |
High_risk | Panobinostat | Launched | HDAC inhibitor | − 0.3713 |
High_risk | Sertindole | Withdrawn | DDopamine receptor antagonist|serotonin RReceptor antagonist | − 0.35991 |
High_risk | Trichostatin-a | Preclinical | HDAC inhibitor | − 0.34601 |
High_risk | Etanidazole | Phase 3 | Bacterial cell wall synthesis inhibitor | − 0.34396 |
Low_risk | Etamsylate | Launched | Haemostatic agent | − 0.3884 |
Low_risk | Belinostat | Launched | HDAC inhibitor | − 0.3655 |
Low_risk | Panobinostat | Launched | HDAC inhibitor | − 0.36209 |
Low_risk | Trichostatin-a | Preclinical | HDAC inhibitor | − 0.36143 |
Low_risk | Tolmetin | Launched | Cyclooxygenase inhibitor | − 0.35756 |
